AstraZeneca Plc is to acquire Ardea Biosciences Inc of San Diego, California which has a late-stage product for gout. The agreed deal values the US company at $1.26 billion, including the target company’s cash balances. Ardea is listed on Nasdaq. ---Subscribe to MedNous to access this article--- Finance, Grants, Deals Company News
